- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05842135
REsectability Small Bowel Obstruction LAParoscopic (RESBOLAP) Score. Multicentric Data Registry (RESBOLAP)
AIM OF THE STUDY The aim of the study is to develop a Resectability Laparoscopic Score as a helpful instrument during intraoperative decision-making in the setting of emergency laparoscopic surgery for small bowel obstruction (SBO) by analyzing a multicenter data registry.
DESIGN OF THE STUDY This is a multicenter study composed of a first phase of prospective data collection from patients that undergo laparoscopic surgery with a diagnosis of SBO and undergo Indocyanine green (ICG) fluorescence angiography (FA) for doubts about bowel viability after the resolution of the obstructive mechanism; the second phase of retrospective analysis to develop the Resectability Score.
METHODS The FA should be performed in all patients undergoing laparoscopic surgery for SBO that presents concerns bowel viability after the resolution of the occlusive mechanism, with consequent intraoperative enrolment in the study Registry.
The investigators adopted the modified Bulkley classification of the fluorescent patterns to identify which patients need more FA to assess bowel vitality.
It is expected that most patients for whom the FA will be performed are those with patterns 2 or 3, representing the study's primary object.
All participant centers must adopt the same technique to perform FA with the attempt to homogenize the procedure.
Twenty-five milligrams of ICG powder is suspended in 10 ml of sterile water and administered intravenously through a peripheral vein and in small repeatable boluses of 2 ml in order to evaluate the intestinal microcirculation extemporaneously. The presence and pattern of arterial supply is tested and compared with that of healthy bowel. Proper clearance of the dye was also appraised to verify adequate venous drainage. Following the reversal of the underlying cause of the ischaemic injury, and after generous irrigation with warm saline, the involved bowel segment was further evaluated with FA after 10 min, regardless of the return of visible peristalsis.
Routine postoperative clinical judgment will be considered sufficient to check bowel vitality.
The need for a second-look surgery and delayed resections will be recorded. All centers could participate with a maximum of 3-4 members (co-authorship) Data will be recorded by a simple and brief online Case Report Form (CRF) on which upload also a photo/brief video of the FA, will be filled out by every participating center for each patient.
A link to a Google Form and the necessary documents will be sent to every center after they have accepted to participate in the study.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Albeit the role of laparoscopy in the treatment of acute small bowel obstruction (SBO) has grown significantly over the last decade, the inability to obtain an adequate evaluation of compromised bowel segments has been considered as real limitation. This is essentially due to a reduced field of view owing to intestinal distension, the minimized haptic feedback obtained and limited bi-dimensional visualization. As a consequence, the presence of normal visual clues to irreversible vascular insufficiency is much reduced.
Such signs include stable discoloration of the bowel wall, absence of peristaltic movements and apparent mesenteric pulsation. Intestinal perfusion and viability are largely assessed by means of the clinical eye. However, this method lacks objectivity and accuracy, irrespective of a surgeon's experience. Routinely clinical judgment may be appropriate, but the rate of conversion due to concerns regarding bowel viability can be high. Where there are concerns for intestinal ischaemic injury without absolute indications to bowel resection (areas of mural gangrene or bowel necrosis with perforation) intestinal compromise can be appraised by real-time fluorescent analysis of the vascular supply.
Some authors reported their experience on the use of the ICG fluorescent angiography (FA) to assess bowel viability during laparoscopic approach in emergency surgery for SBO, with promising results. Nowadays, an important drawback of qualitative intraoperative assessment of bowel compromise with FA is the interpretation and definition of the boundaries between bowel viability and irreversible ischemia in order to avoid or reduce the rate of delayed bowel necrosis and perforation. An instrument more objective as possible to help surgeons during the intraoperative decision-making is lacking. A resectability score could be resolutive but a large amount of data from a multicentric data registry is needed.
Finally, when the registry will be completed, a logistic regression analysis will be used to identify independent predictive factors of bowel resectability by calculation of odds ratios and its 95% CI based on delayed bowel resection rate too. Significant continuous variables will be transformed into categorical variables using receiver operating characteristic (ROC) curves. The sample size required for the development of the Score was determined according to previous reports. The number of unnecessary bowel resections has been estimated around 46%. Two studies on ICG-fluorescence angiography use during laparoscopic surgery for SBO reported 28.6% of resection rate. The investigators adopted this degree of difference as the maximum error tolerance of 17.4%. Considering a power of 0.9 , a significance level of 0.05 , a 95% CI with its two sides of 0.112 and 0.46, the required sample size will be of 26 subjects that will undergo to bowel resection that must be associated with other 26 subjects with no bowel resection and other 26 will undergo delayed bowel resection, for a total of 78 patients. According to this sample size the score will have a sensitivity of 0.28, a specificity of 0.73, a positive predictive value of 0.22, a negative predictive value of 0.73 and a precision value of 0.39.
The optimal cut-off point with the highest sum of sensitivity and specificity will be chosen for each variable, also the overall predictive value of the Score will be assessed. Finally, a score will be developed by assigning coefficient points to each variable.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Locations
-
-
Pesaro-Urbino
-
Pesaro, Pesaro-Urbino, Italy, 61121
- Department of General Surgery, San Salvatore Hospital , AST Pesaro-Urbino
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- All centers that routinely perform emergency laparoscopic surgery for SBO and have imaging systems with technology for the detection of near-infrared/indocyanine green fluorescence
- All patients more than 18 years old undergoing emergency laparoscopic surgery for SBO with intraoperative doubts about bowel viability after the resolution of the occlusive mechanism
Exclusion Criteria:
- Open surgical procedure for SBO
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Development of a resectability laparoscopic score based on data of a multicentric data registry
Time Frame: Event occurred at the time of surgery or after the first surgical interventional without bowel resection
|
Based on these items a resectability laparoscopic score is developed:
|
Event occurred at the time of surgery or after the first surgical interventional without bowel resection
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Development of a multicentric data registry of patients underwent laparoscopic approach to small bowel obstruction and ICG fluorescent angiography
Time Frame: 12 months eventually extended by further 6 months
|
A Data Registry is constructed from multicentric data
|
12 months eventually extended by further 6 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: DIEGO COLETTA, MD, San Salvatore Hospital, AST Pesaro-Urbino
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CERP22078
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Small Bowel Obstruction
-
North-Western State Medical University named after...RecruitingSmall Bowel Obstruction | Small Bowel Obstruction Adhesion | Small-Bowel Obstruction Due to Volvulus | Hernia IncarceratedRussian Federation
-
Queen Savang Vadhana Memorial Hospital, ThailandNot yet recruitingSmall Bowel Obstruction | Small Bowel Adhesion
-
Florida Hospital Tampa Bay DivisionCompletedColectomy | Small Bowel Obstruction | Bowel Surgeries
-
Yale UniversityTerminatedSmall Bowel ObstructionUnited States
-
Danish Small Bowel Obstruction CollaborativeActive, not recruiting
-
Helsinki University Central HospitalCompleted
-
University of TartuNorth Estonian Medical CenterCompleted
-
Groupe Hospitalier Paris Saint JosephActive, not recruiting
-
European Society for Trauma and Emergency SurgeryNot yet recruiting
-
University of TartuNorth Estonian Medical CenterRecruiting
Clinical Trials on Laparoscopic approach to small bowel obstrcuction
-
US Department of Veterans AffairsCompleted
-
GlaxoSmithKlineCompleted
-
University of British ColumbiaCompleted